TABLE 2.
Characteristic of selected studies.
| Sample | Male (%) | Mean age (years) | Disease | Component of PNP | Antiplatelet treatment regimen | Outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | PNP plus ASA/ASA | PNP plus ASA/ASA | PNP plus ASA/ASA | PNP plus ASA | ASA | Intervention time | Test time | Primary | Secondary | ||
| Zhou et al. (2008) | 40/40 | 52.5/55 | 69.90 ± 10.71/71.16 ± 10.60 | ischemic stroke | PTS | Sanqi Tongshu capsule 200 mg tid + ASA 100 mg qd | ASA 100 mg qd | 6 m | 3m; 6 m | PAgR | ①; ②; ③; ④; ⑤ |
| Li, (2011) | 27/28 | 48.15/53.57 | 74.25 ± 6.32/76.32 ± 9.04 | coronary heart disease | PTS | Sanqi Tongshu capsule 200 mg tid + ASA 100 mg qd | ASA 100 mg qd | 6 m | 6 m | PAgR; PT; PT-INR; DD | ④; ⑥; ⑦ |
| Yan and Cui, (2015) | 28/29 | NR/NR | NR/NR | ischemic stroke | PTS | Sanqi Tongshu capsule 200 mg tid + ASA 100 mg qd | ASA 100 mg qd | 6 m | 6 m | PAgR; PT; PT-INR; DD | ⑦ |
| Wu, (2016) | 100/100 | 55/57 | 58.64 ± 7.13/58.58 ± 7.08 | ischemic stroke | PNS | Xuesaitong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | PAgR; PLT; FIB; DD | ⑤ |
| Zong et al. (2009) | 40/40 | 67.5/62.5 | 51 ± 11/53 ± 9 | angina pectoris | PNS | Xuesaitong injection 400 mg qd + ASA 50 mg qd | ASA 50 mg qd | 2w | 2w | PAgR | NR |
| Cheng et al. (2014) | 33/30 | 54.55/56.67 | 59.8 ± 6.7/60.6 ± 6.4 | acute ischemic stroke | PNS | Xuesaitong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | PAgR; PLT; FIB; DD | NR |
| Li, (2021) | 45/40 | 64.44/65 | 59 ± 12.59/58 ± 8.15 | acute ischemic stroke | PNS | Xuesaitong soft capsule 660 mg bid + ASA 100 mg qd | ASA 100 mg qd | 3 m | 3 m | PLT; PT | NR |
| Chen et al. (2018) | 60/60 | 51.67/50 | 63.87 ± 11.02/64.29 ± 11.36 | ischemic stroke | PNS | Xuesaitong tablet 50–100 mg tid + ASA 100–200 mg qd | ASA 100–200 mg qd | 3w | 3w | PAgR | NR |
| Zhang (2013) | 40/40 | 52.5/55 | 55.14 ± 6.28/55.36 ± 6.19 | unstable angina | PNS | Xuesaitong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | PAgR; FIB | NR |
| Piao (2012) | 28/29 | 53.57/55.17 | 72.89 ± 8.45/75.62 ± 6.30 | ischemic stroke | PTS | Sanqi Tongshu capsule 200 mg tid + ASA 100 mg qd | ASA 100 mg qd | 6 m | 6 m | PAgR; PT; PT-INR; DD | ④; ⑥; ⑦ |
| Yang (2014) | 50/50 | 58/54 | 65.55 ± 12.72/64.52 ± 12.36 | ischemic stroke | PNS | Xuesaitong soft capsule 660 mg bid + ASA 100–300 mg qd | ASA 100–300 mg qd | 3w | 3w | PLT | NR |
| Sun (2019) | 168/168 | 57.14/53.57 | 64.2 ± 8.7/65.4 ± 8.4 | ischemic stroke | PNS | Xuesaitong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | PLT | NR |
| Wang et al. (2021) | 20/20 | 85/90 | 57.5 ± 4.07/55.75 ± 5.14 | stable coronary heart disease | PNS | Xuesaitong soft capsule 660 mg bid + ASA 100 mg qd | ASA 100 mg qd | 2 m | 2 m | PAgR | NR |
| Xue (2018) | 36/36 | 52.78/55.56 | 58.18 ± 6.52/57.89 ± 6.85 | ischemic stroke with middle cerebral artery stenosis | PNS | Xuesaitong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 4w | 4w | FIB | ④ |
| Shen (2017) | 123/123 | 51.22/50.41 | 64.33 ± 10.25/64.35 ± 10.64 | ischemic stroke | PTS | Sanqi Tongshu capsule 200 mg tid + ASA 100–300 mg qd | ASA 100–300 mg qd | 3w | 3w | PAgR | NR |
| Ma et al. (2017) | 40/40 | 65/50 | 55.82 ± 12.11/57.23 ± 10.21 | acute ischemic stroke | PNS | Xueshuantong injection 500 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | FIB | NR |
| Hu (2016) | 40/40 | 55/52.5 | 61.2 ± 12.3/60.1 ± 12.6 | acute ischemic stroke | PNS | Xueshuantong injection 400 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | FIB; DD | NR |
| Yu et al. (2014) | 34/34 | 52.94/58.82 | 58.5 ± 9.7/55.1 ± 11.2 | acute ischemic stroke | PNS | Xueshuantong injection 500 mg qd + ASA 100 mg qd | ASA 100 mg qd | 2w | 2w | FIB | NR |
| Zhong et al. (2011) | 38/38 | 56.58 (all) | NR/NR | ischemic stroke | PNS | Xuesaitong tablet 50–100 mg tid + ASA 100 mg qd | ASA 100 mg qd | 12 m | 12 m | PAgR | NR |
| Zhang et al. (2010) | 120/121 | 56.67/53.72 | 67.2/65.3 | acute ischemic stroke | PNS | Xuesaitong tablet 200 mg tid + ASA 100 mg qd | ASA 100 mg qd | 12 m | 12 m | PAgR | NR |
Note: ① upper gastrointestinal bleeding; ② bulbar conjunctival hemorrhage; ③ hematuria; ④ gastrointestinal side effects; ⑤ urticaria; ⑥ subcutaneous hemorrhage; ⑦ positive fecal occult blood.
Abbreviations: PNP, panax notoginseng preparation; ASA, aspirin; NR, not reported; PTS, panaxatriol saponin; PNS, panax notoginseng saponin; tid, three times a day; qd, once daily; bid, twice a day; PAgR, platelet aggregation rate; PLT, platelet count; PT, prothrombin time; PT-INR, prothrombin time-based international normalized ratio; FIB, fibrinogen; DD, D-dimer.